Producer
Cambridge Isotope Laboratories (CIL)
US-based stable isotope manufacturer and distributor; one of the world's largest commercial suppliers of 13C-labeled compounds, deuterium-labeled compounds, and other stable isotopes for pharmaceutical research and diagnostics. Manufactures 13C-urea for H. pylori breath tests and custom-labeled pharmaceuticals for metabolism studies. Subsidiary of Merck KGaA (MilliporeSigma) since 2017, though operated with significant operational independence.
1
Inputs supplied
0
Goods downstream
1
Facilities
0
Stories
What they make
1 input Cambridge Isotope Laboratories (CIL) supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
What else they do
Business segments
The company's full revenue map — where this supply-chain role fits within their broader business.
NMR & Spectroscopy Solvents
30%Pharmaceutical R&D Labeled Compounds
35%Stable Isotope Raw Materials
20%Analytical & Diagnostic Isotopes
15%
Intelligence
What's known
Sourced claims about this company's role in supply chains — chokepoints, concentration, incidents, dual-use connections.
Origin2022
Cambridge Isotope Laboratories (CIL), founded in 1981 in Woburn (now Tewksbury), Massachusetts, and acquired by Merck KGaA (German specialty science company) in 2016, is the world's leading producer of stable isotope-labeled compounds — molecules in which specific atoms have been substituted with heavier isotopes of the same element (deuterium for hydrogen, carbon-13 for carbon-12, nitrogen-15 for nitrogen-14). These labeled compounds are invisible to most supply chain analyses but are ubiquitous in pharmaceutical research: every drug candidate that enters clinical development undergoes ADME (absorption, distribution, metabolism, excretion) studies using isotope-labeled versions of the drug to trace its metabolic fate. CIL's CDCl3 (deuterated chloroform) is the NMR spectroscopy solvent used in the majority of the world's chemistry research — nearly every carbon or proton NMR spectrum run in every pharmaceutical, academic, or industrial chemistry laboratory globally uses CIL or one of its few competitors' deuterated solvents. The company also manufactures deuterated intermediates for deuterated drug development: the first FDA-approved deuterated drug (AUSTEDO, deutetrabenazine, Teva, 2017) uses the kinetic isotope effect — deuterium's stronger C-D bond vs. C-H bond — to slow metabolic clearance and improve the drug's pharmacokinetic profile. CIL is a scientific infrastructure company whose products appear inside every modern drug development program but whose name appears in no consumer context.
Cambridge Isotope Laboratories, Inc. ↗